Madrigal Pharmaceuticals Inc (MDGL)

Mar 11, 2025, 8:00 AM EDT - 23 days ago

Madrigal Appoints Jacqualyn A. Fouse, Ph.D.

Feb 28, 2025, 2:29 PM EST - 4 weeks ago

Madrigal Pharmaceuticals: Rezdiffra First-Mover Advantage Gains Traction (Upgrade)

Feb 26, 2025, 6:33 PM EST - 5 weeks ago

Madrigal CEO on Q4 earnings beat, MASH drug market opportunity

Feb 26, 2025, 12:28 PM EST - 5 weeks ago

Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis

Feb 26, 2025, 11:41 AM EST - 5 weeks ago

Madrigal Pharmaceuticals Q4 Earnings Review: Strong Quarter, Even Stronger Outlook

Feb 26, 2025, 11:05 AM EST - 5 weeks ago

Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 7:00 AM EST - 5 weeks ago

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Feb 26, 2025, 6:30 AM EST - 5 weeks ago

Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Feb 21, 2025, 8:00 AM EST - 5 weeks ago

Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference

Feb 12, 2025, 8:00 AM EST - 7 weeks ago

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025

Jan 29, 2025, 11:50 AM EST - 2 months ago

MoneyShow's Best Investment Ideas For 2025: Part 7

ARCC ASML HESM IMMR MARA TOST VLGEA

Jan 19, 2025, 9:30 AM EST - 2 months ago

Madrigal Pharmaceuticals Rezdiffra Vies For Blockbuster Status In MASH

Jan 13, 2025, 6:45 AM EST - 2 months ago

Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra

Jan 9, 2025, 6:22 AM EST - 3 months ago

Fast Drug Launch For Madrigal Pharmaceuticals Brings Buyout Discussion

Jan 8, 2025, 11:13 AM EST - 3 months ago

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

AMGN BBIO BMY IOVA LLY MRK PFE

Jan 3, 2025, 8:00 AM EST - 3 months ago

Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 25, 2024, 8:29 AM EST - 4 months ago

Top 3 Health Care Stocks That May Dip This Month

BFLY CNMD

Nov 6, 2024, 8:00 AM EST - 5 months ago

Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences

Nov 3, 2024, 9:00 AM EST - 5 months ago

Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion

Oct 31, 2024, 2:50 PM EDT - 5 months ago

Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 8:00 AM EDT - 5 months ago

Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®

Oct 28, 2024, 3:42 AM EDT - 5 months ago

Madrigal Pharmaceuticals: Looking To Finally Establish A Position Around The Q3 Earnings

Oct 24, 2024, 12:11 PM EDT - 5 months ago

Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings

Oct 21, 2024, 8:00 AM EDT - 5 months ago

Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis

Oct 18, 2024, 8:00 AM EDT - 5 months ago

Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024

Oct 2, 2024, 8:00 AM EDT - 6 months ago

Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference

Aug 8, 2024, 4:21 PM EDT - 8 months ago

While Madrigal's Rezdiffra Impresses, Great Uncertainties Loom In MASH Market

Aug 7, 2024, 11:23 AM EDT - 8 months ago

Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 7:00 AM EDT - 8 months ago

Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates

Aug 2, 2024, 7:00 AM EDT - 8 months ago

Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel

Jul 24, 2024, 8:00 AM EDT - 9 months ago

Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024

Jun 13, 2024, 7:28 PM EDT - 10 months ago

Madrigal Pharma CEO talks competition in the GLP-1 space and new drug rollouts

Jun 12, 2024, 10:16 AM EDT - 10 months ago

Madrigal Pharmaceuticals: The GLP-1 Threat May Be Overcooked

Jun 6, 2024, 8:00 AM EDT - 10 months ago

Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress

May 7, 2024, 11:24 AM EDT - 11 months ago

Madrigal Pharmaceuticals (MDGL) Q1 2024 Earnings Call Transcript

May 7, 2024, 7:00 AM EDT - 11 months ago

Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

Apr 30, 2024, 4:30 PM EDT - 1 year ago

Madrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-Label

Apr 24, 2024, 4:00 PM EDT - 1 year ago

Madrigal Statement on the Passing of Dr. Stephen Harrison

Apr 16, 2024, 4:05 PM EDT - 1 year ago

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Mar 18, 2024, 11:58 PM EDT - 1 year ago

Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering

Mar 18, 2024, 4:04 PM EDT - 1 year ago

Madrigal Pharmaceuticals Announces Proposed Public Offering

Mar 18, 2024, 10:15 AM EDT - 1 year ago

Madrigal: Accelerated Rezdiffra Approval Puts It In The NASH Lead

Mar 15, 2024, 7:06 AM EDT - 1 year ago

Madrigal Pharma surges on FDA nod to first drug for fatty liver disease NASH

Mar 14, 2024, 6:21 PM EDT - 1 year ago

FDA approves Madrigal Pharmaceuticals drug as first treatment for common NASH liver disease

Mar 14, 2024, 4:44 PM EDT - 1 year ago

Madrigal Pharmaceuticals gets first FDA approval for drug targeting liver disease MASH

Mar 14, 2024, 4:15 PM EDT - 1 year ago

Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis

Mar 14, 2024, 4:14 PM EDT - 1 year ago

Madrigal's drug wins first US approval for fatty liver disease NASH as rivals circle

Mar 14, 2024, 3:53 PM EDT - 1 year ago

US FDA approves first drug for fatty liver disease NASH

Feb 28, 2024, 7:01 AM EST - 1 year ago

Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer

Feb 28, 2024, 7:00 AM EST - 1 year ago

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results